Cardiovascular safety of COX-2 inhibitors.
D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects*; D000068579:Celecoxib; D003257:Consumer Product Safety; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones; D013927:Thrombosis / Q000139:chemically induced*
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib